Business Insider
My Markets Watchlist
Markets Stocks

Sanofi S.A. Stock , SNYNF

84.34 EUR -1.76 -2.04%
12:02:49 PM STU
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Sanofi Stock Snapshot

120.97 B
Market Cap in USD
1.22 B
Number of Shares
1.22 B
Total Number of Shares
3.92
Dividend in EUR
4.18
Dividend Yield
21.10
P/E Ratio
91.49
Free Float in %
4.44
EPS in EUR
61.83
Book Value per Share in EUR
7.23
Cash Flow per Share in EUR

Historical Prices for Sanofi

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Sanofi Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price

Sanofi Estimates* in EUR

  2025 2026 2027 2028 2029
Revenue 45,772 48,918 51,881 53,692 56,962
Dividend 4.14 4.35 4.61 4.80 5.38
Dividend Yield (in %) 4.78 % 5.03 % 5.33 % 5.54 % 6.22 %
EPS 8.10 8.83 9.44 10.42 11.49
P/E Ratio 10.68 9.79 9.16 8.30 7.53
EBIT 12,335 13,205 14,099 15,614 16,896
EBITDA 14,300 15,190 15,868 17,510 18,744
Net Profit 9,890 10,639 11,378 12,612 13,916
Net Profit Adjusted 9,890 10,639 11,378 12,612 13,916
Pre-Tax Profit - - - 15,587 17,380
Pre-Tax Profit Reported 8,573 9,557 10,384 13,014 15,712
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 6.82 7.36 8.14 8.96 10.19
Gross Income 32,989 35,644 38,089 41,306 44,110
Cash Flow from Investing 5,633 -2,546 -2,698 -3,197 -3,298
Cash Flow from Operations 10,361 11,717 12,671 13,563 14,902
Cash Flow from Financing -12,243 -7,526 -6,621 -7,247 -7,452
Cash Flow per Share 9.01 9.73 10.65 12.40 13.29
Free Cash Flow 9,338 8,882 9,726 10,515 11,788
Free Cash Flow per Share 7.11 7.45 8.16 - 9.59
Book Value per Share 65.27 68.36 72.03 81.50 80.70
Net Debt 5,559 2,807 -1,458 -1,808 -7,417
Research & Development Exp. 7,630 7,998 8,251 8,399 8,818
Capital Expenditure 2,639 2,744 2,852 3,091 3,202
Selling, General & Admin. Exp. 9,386 9,726 9,999 10,227 10,581
Shareholder’s Equity 79,588 83,068 87,577 96,707 99,036
Total Assets 132,845 136,129 140,713 141,524 147,288
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts 9 7 7 21 20
Average Estimate 1.686 EUR 1.653 EUR 3.055 EUR 8.100 EUR 8.834 EUR
Year Ago - - - 4.443 EUR -
Publish Date 4/24/2025 7/31/2025 10/24/2025 - -
Revenue Estimates
No. of Analysts 9 7 7 19 19
Average Estimate 10,126 EUR 10,319 EUR 13,327 EUR 45,772 EUR 48,918 EUR
Year Ago - - - 41,081 EUR -
Publish Date 4/24/2025 7/31/2025 10/24/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. EUR

2024 2023 2022 2021 2020 2019 2018
Sales 41,081.00 43,070.00 42,997.00 37,761.00 36,041.00 36,126.00 34,463.00
Change of sales in % -4.62 0.17 13.87 4.77 -0.24 4.83 -1.69
Gross profit on sales 25,994.00 26,498.00 27,142.00 23,814.00 22,086.00 21,856.00 20,740.00
Gross profit on sales change in % -1.90 -2.37 13.97 7.82 1.05 5.38 -3.36
Operating income 9,506.00 9,183.00 10,031.00 8,668.00 7,273.00 6,078.00 5,081.00
Operating income change in % 3.52 -8.45 15.72 19.18 19.66 19.62 -15.53
Income before tax 6,698.00 7,153.00 10,422.00 7,798.00 13,804.00 2,822.00 4,405.00
Income before tax change in % -6.36 -31.37 33.65 -43.51 389.16 -35.94 -20.34
Income after tax 5,496.00 5,400.00 8,371.00 6,223.00 12,314.00 2,907.00 4,319.00
Income after tax change in % 1.78 -35.49 34.52 -49.46 323.60 -32.69 13.93

Balance Sheet in Mio. EUR

2024 2023 2022 2021 2020 2019 2018
Total liabilities 54,941.00 52,111.00 51,570.00 51,211.00 51,382.00 53,628.00 52,373.00
Long-term liabilities per share 22.26 22.31 22.04 23.88 25.69 26.52 28.10
Equity 77,857.00 74,353.00 75,152.00 69,031.00 63,147.00 59,108.00 59,035.00
Equity change in % 4.68 -0.99 8.89 9.02 6.90 0.10 1.35
Balance sheet total 132,798.00 126,464.00 126,722.00 120,242.00 114,529.00 112,736.00 111,408.00
Balance sheet total change in % 5.01 -0.20 5.39 4.99 1.59 1.19 11.60

Key Data in EUR

2024 2023 2022 2021 2020 2019 2018
Sales per share 32.71 34.28 34.21 30.02 28.60 28.74 27.46
P/E ratio (year end quote, basic EPS) 21.10 20.81 13.44 17.83 8.01 38.53 21.85
P/E ratio (year end quote, diluted EPS) 21.18 20.88 13.49 17.91 8.05 38.75 21.99
Dividend yield in % 4.18 4.19 3.96 3.76 4.07 3.51 4.06
Equity ratio in % 58.63 58.79 59.30 57.41 55.14 52.43 52.99
Debt ratio in % 41.37 41.21 40.70 42.59 44.86 47.57 47.01

Sanofi Dividend Calendar

Date Name Dividend *yield Currency
2024 Sanofi S.A. 3.92 4.18 EUR
2023 Sanofi S.A. 3.76 4.19 EUR
2022 Sanofi S.A. 3.56 3.96 EUR
2021 Sanofi S.A. 3.33 3.76 EUR
2020 Sanofi S.A. 3.20 4.07 EUR
2019 Sanofi S.A. 3.15 3.51 EUR
2018 Sanofi S.A. 3.07 4.06 EUR
2017 Sanofi S.A. 3.03 4.22 EUR
2016 Sanofi S.A. 2.96 3.85 EUR
2015 Sanofi S.A. 2.93 3.73 EUR
2014 Sanofi S.A. 2.85 3.77 EUR
2013 Sanofi S.A. 2.80 3.63 EUR
2012 Sanofi S.A. 2.77 3.88 EUR
2011 Sanofi S.A. 2.65 4.67 EUR
2010 Sanofi S.A. 2.50 5.22 EUR
2009 Sanofi S.A. 2.40 4.36 EUR
2008 Sanofi S.A. 2.07 4.56 EUR
2007 Sanofi S.A. 1.75 2.78 EUR
2006 Sanofi S.A. 1.52 2.17 EUR
2005 Sanofi S.A. 1.20 1.62 EUR
2004 Sanofi S.A. 1.02 1.73 EUR
2003 Sanofi S.A. 0.84 1.41 EUR
2002 Sanofi S.A. 0.66 1.13 EUR
2001 Sanofi S.A. 0.44 0.53 EUR
*Yield of the Respective Date

Sanofi Calendar

Event Estimate Info Date
Earnings Report 1.653 EUR Q2 2025 Earnings Release 07/31/2025
Earnings Report 3.055 EUR Q3 2025 Earnings Release 10/24/2025
Earnings Report 1.584 EUR Q4 2025 Earnings Release 01/30/2026
Earnings Report 1.725 EUR Q1 2026 Earnings Release 04/23/2026
Earnings Report 1.880 EUR Q2 2026 Earnings Release 07/23/2026
Earnings Report 3.380 EUR Q3 2026 Earnings Release 10/23/2026

Sanofi Past Events

Event Actual EPS Info Date
Annual General Meeting 4.440 EUR Annual General Meeting 04/30/2025
Earnings Report - Q2 2024 Earnings Release 07/25/2024
Annual General Meeting 4.310 EUR Annual General Meeting 04/30/2024
Earnings Report - Q4 2023 Earnings Release 02/01/2024
Annual General Meeting 6.690 EUR Annual General Meeting 05/25/2023
Earnings Report - Q4 2022 Earnings Release 02/03/2023
Earnings Report - Q3 2022 Earnings Release 10/28/2022
Annual General Meeting 4.970 EUR Annual General Meeting 05/03/2022
Earnings Report - Q1 2022 Earnings Release 04/28/2022
Earnings Report - Q4 2021 Earnings Release 02/04/2022

Sanofi Profile

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Sanofi Management

Name Job
Emmanuel Frenehard Chief Digital Officer & Executive Vice President
Raj Verma Chief Diversity, Culture & Experience Officer
Paul Hudson Chief Executive Officer & Executive Director
François-Xavier Michel Marie Roger Chief Financial Officer
Natalie Bickford Chief People Officer & Executive Vice President
Preethi Sundaram Director-Global Clinical Research
Houman Ashrafian Executive VP, Head-Research & Development
Brendan OCallaghan Executive VP-Global Manufacturing & Supply
Roy Papatheodorou Executive Vice President & General Counsel
Audrey Duval Derveloy Executive Vice President & Head-Corporate Affairs
Madeleine Roach Executive Vice President-Business Operations
Julie van Ongevalle Executive Vice President-Consumer Healthcare
Olivier Antoine M. Charmeil Executive Vice President-General Medicines
Christopher Corsico Global Head-Development
Thomas Kudsk Larsen Head-Investor Relations
Alexandra Roger Head-Legal Corporate & Finance
Frédéric Oudéa Independent Chairman
Anne-Francoise Nesmes Independent Director
Antoine Yver Independent Director
Carole Gabriella Ferrand Independent Director
Clotilde Delbos Independent Director
Emile Voest Independent Director
Fabienne Lecorvaisier Independent Director
Jean-Paul Kress Independent Director
John Sundy Independent Director
Lise Kingo Independent Director
Patrick Kron Independent Director
Rachel Duan Independent Director
Barbara Lavernos Non-Independent Director
Christophe Babule Non-Independent Director
Wolfgang Laux Non-Independent Director
Yann Tran Non-Independent Director